NDRA

ENDRA Life Sciences Inc. (NDRA) - 10-Q Summary

Business Context and Reporting Period

This Quarterly Report on Form 10-Q covers the period ended June 30, 2026. ENDRA Life Sciences Inc. is a biotechnology company developing the Thermo-Acoustic Enhanced Ultrasound (TAEUS) platform for liver fat measurement and metabolic disease management. In 2025, the company adopted a Digital Asset Treasury (DAT) strategy to generate non-dilutive returns. On June 25, 2026, the company entered into a Merger Agreement to acquire Noble Africa LLC (a subsidiary of ASP Isotopes Inc.), which holds Renergen Limited, a South African energy company focused on helium and LNG.

Key Financial Metrics

Material Changes vs. Prior Period

• Net Loss Reduction: The net loss decreased by approximately $1.11 million compared to the prior year period, primarily driven by significant unrealized and realized gains on digital assets ($2.56 million total) which offset operating losses.
• Operating Expenses: Total operating expenses increased by $886,632 (32%) year-over-year. General and Administrative (G&A) expenses rose by $914,037, largely due to a $1.12 million increase in stock-based compensation. Conversely, Sales and Marketing expenses dropped by 93% due to restructuring.
• Liquidity Position: Total cash increased significantly to $5.54 million, driven by a $3.8 million private placement in May 2026. However, $3.8 million of this is restricted cash held in a segregated account pending the merger or repayment obligations.
• Digital Asset Activity: The company sold approximately 50,271 HYPE tokens during the six-month period, recognizing a realized gain of $530,940. The remaining holdings are valued at $1.9 million.

Guidance, Outlook, Risks, and Unusual Items

• Merger Transaction: The company is pursuing a merger with Noble Africa/ASP Isotopes. This transaction is subject to stockholder approval and other conditions. If the merger fails, the company may be required to return the $3.8 million private placement proceeds to the investor.
• Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern without the consummation of the merger or additional financing. The company has an accumulated deficit of over $111 million and no product revenue.
• Unusual Items: The financial results are heavily influenced by non-operating items, specifically the fair value changes of digital assets and warrant liabilities. The company recorded a $2.03 million unrealized gain and a $0.53 million realized gain on digital assets.
• Internal Controls: The company identified a material weakness in internal controls over financial reporting due to insufficient personnel to segregate duties.
• Nasdaq Compliance: The company regained compliance with Nasdaq stockholders' equity requirements in July 2026 but is subject to a one-year discretionary panel monitor.

Investor Verification Checklist

• Merger Status: Verify the progress of the Noble Africa merger and the likelihood of stockholder approval, as this is critical to the company's liquidity and survival.
• Restricted Cash Usage: Confirm the terms of the side letter agreement regarding the $3.8 million restricted cash and the conditions under which it must be returned to the investor.
• Digital Asset Volatility: Assess the risk exposure to the HYPE token holdings and the sustainability of the Digital Asset Treasury strategy given market volatility.
• Capital Runway: Evaluate the company's ability to fund operations beyond the current quarter if the merger does not close, considering the limited unrestricted cash ($1.74 million).
• Stock-Based Compensation: Review the impact of the $1.12 million stock-based compensation expense on future cash burn and dilution.